Table 1.

Randomized trials of implantable cardioverter defibrillators

Study	N	Inclusion criteria	Intervention	Follow-up (median)	All-cause mortality	SCD
CAT [13]	104	LVEF < 30% NYHA 2–3	ICD vs OMT	23 months	Terminated early
AMIOVIRT [12]	103	LVEF ≤ 35% NYHA 1–3 NSVT	ICD vs amio	24 months	Terminated early
SCDHeFT (DCM cohort) [10]	1211	LVEF < 35% NYHA 2–3	ICD vs OMT vs amio	46 months	I 21.4%, C 27.9% (5 years) HR 0.73; 95% CI 0.50–1.07 p = 0.06
DEFINITE [11]	458	LVEF < 36% NYHA 1–3 NSVT or PVCs	ICD vs OMT	29 months	I 12.2%, C 17.4% HR 0.65; 95% CI 0.40–1.06 p = 0.08	I 1.3%, C 6.1% HR 0.20; 95% CI 0.06–0.71 P = 0.006
DANISH [16]	1116	LVEF < 35% NYHA 2–3 (4 if CRT) NT-pro-BNP > 200 pg/ml	ICD vs OMT	68 months	I 21.6%, C 23.4% HR 0.87; 95% CI 0.68–1.12 p = 0.28	I 4.3%, C 8.2% HR 0.50; 95% CI 0.31–0.82 p = 0.005

Randomized trials investigating effect of implantable cardioverter defibrillators in patients with dilated cardiomyopathy without a history of haemodynamically unstable ventricular arrhythmia

amio amiodarone, C optimal medical therapy arm, CI confidence interval, CRT cardiac resynchronisation therapy, HR hazard ratio, I implantable cardioverter defibrillator therapy arm, ICD implantable cardioverter defibrillator, LVEF left ventricular ejection fraction, NYHA New York Heart Association, NT-pro-BNP N-terminal-pro-peptide brain natriuretic peptide, NSVT non-sustained ventricular tachycardia, PVCs premature ventricular complexes, OMT optimal medical therapy, SCD sudden cardiac death

(Reproduced with permission from: Halliday et al. Circulation [Internet]. 2017;136:215–31. Available from: http://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.116.0271340) [9]